Mycophenolate mofetil Alternatives Compared
| Mycophenolate mofetil | Ultomiris (ravulizumab) | Rystiggo (rozanolixizumab) |
|
|---|
| Mycophenolate mofetil | Ultomiris (ravulizumab) | Rystiggo (rozanolixizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Autoimmune Hepatitis, Bullous Pemphigoid, Crohn's Disease, Cogan's Syndrome, Organ Transplant - Rejection Prophylaxis, Dermatomyositis, Evan's Syndrome, Graft Versus Host Disease, High... View more |
Prescription only
Prescribed for Myasthenia Gravis, Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Neuromyelitis Optica Spectrum Disorder. Ultomiris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Myasthenia Gravis. Rystiggo may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||||||||||||||||||
| More about Mycophenolate mofetil | More about Ultomiris (ravulizumab) | More about Rystiggo (rozanolixizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Mycophenolate mofetil has an average rating of 7.9 out of 10 from a total of 60 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 12% reported a negative effect. |
Ultomiris has an average rating of 9.6 out of 10 from a total of 7 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Rystiggo has an average rating of 8.0 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Mycophenolate mofetil side effects |
View all Ultomiris side effects |
View all Rystiggo side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Mycophenolate mofetil prices |
View all Ultomiris prices |
View all Rystiggo prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| CellCept, Myhibbin |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
18 hours |
1192.8 hours |
N/A |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 347 drugs are known to interact with Mycophenolate mofetil:
|
A total of 84 drugs are known to interact with Ultomiris:
|
A total of 294 drugs are known to interact with Rystiggo:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
May 03, 1995 |
December 21, 2018 |
June 26, 2023 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
CellCept
Cellcept (mycophenolate mofetil) is used to prevent rejection of a kidney, liver, or heart ...
Imuran
Imuran is used for atopic dermatitis, autoimmune hepatitis, chronic active hepatitis, chronic ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Prograf
Prograf is used to prevent your body from rejecting a heart, liver, or kidney transplant. Learn ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Envarsus XR
Envarsus XR is used for organ transplant, rejection prophylaxis
Rapamune
Rapamune (sirolimus) is used to prevent rejection in people who have received a kidney transplant ...
Sandimmune
Sandimmune is used for organ transplant, rejection prophylaxis
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.